VG Life Sciences Inc. announced positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), developed with VGLS' proprietary metabolic disruption technology (MDT), in combination with sorafenib (marketed as Nexavar(R)), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00005 USD | -50.00% | -.--% | +4,900.00% |
1st Jan change | Capi. | |
---|---|---|
+4,900.00% | 2.11M | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- VGLS Stock
- News VG Life Sciences Inc.
- VG Life Sciences Inc. Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial